Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies (Tables)

v3.24.1.u1
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
9 Months Ended
Mar. 31, 2024
Notes Tables  
Schedule of restructuring charges

The restructuring and restructuring-related charges, including the impairment of assets held-for-sale, for periods presented were recorded in the Condensed Consolidated Statements of Earnings as follows (in thousands):

Quarter Ended

Nine Months Ended

March 31, 

March 31, 

2024

2024

Cost of sales

$

647

$

1,821

Selling, general and administrative(1)

903

11,153

Total

$

1,550

$

12,974

(1) Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs.

Restructuring and restructuring-related costs by segment are as follows (in thousands):

Three months ended March 31, 2024

Employee

Asset-related

Impairment of

severance

and other

assets held-for-sale

Total

Protein Sciences

$

28

$

914

$

$

942

Diagnostics and Genomics

265

90

355

Corporate

117

136

253

Total

$

410

$

1,140

$

$

1,550

Nine months ended March 31, 2024

Employee

Asset-related

Impairment of

severance

and other

assets held-for-sale

Total

Protein Sciences

$

2,978

$

1,386

$

6,038

$

10,402

Diagnostics and Genomics

1,004

90

1,094

Corporate

1,310

168

1,478

Total

$

5,292

$

1,644

$

6,038

$

12,974

The following table summarizes the changes in the Company’s accrued restructuring balance, which is included within Other current liabilities in the accompanying balance sheet. Other amounts reported as restructuring and restructuring-related costs in the accompanying statements of income have been summarized in the notes to the table (in thousands):

Employee

Asset-related

Impairment of

severance(1)

and other(2)

assets held-for-sale

Total

Expense incurred in the second quarter of 2024

$

4,882

$

504

$

6,038

$

11,424

Cash payments

(1,257)

(177)

(1,434)

Non-cash adjustments

(191)

(6,038)

(6,229)

Accrued restructuring actions balance as of December 31, 2023

$

3,625

$

136

$

$

3,761

Incremental expense incurred in the third quarter of 2024

133

1,140

1,273

Cash payments

(2,806)

(433)

(3,239)

Non-cash adjustments

(843)

(843)

Adjustments(3)

277

277

Accrued restructuring actions balance as of March 31, 2024

$

1,229

$

$

$

1,229

(1) Relates to impacted employees’ final paycheck, separation payments, outplacement services, legal fees, and retention packages related to the closure or sale of certain distribution and manufacturing sites.

(2) Primarily relates to impairment of right-of-use assets, lease termination fees, consulting fees, and expenses for changes to supporting IT systems that are enabling the Company to complete the restructuring initiatives.

(3) Relates to the refinement of the accrual recorded in the second quarter of fiscal 2024.

Protein Sciences | QT Holdings Corporation  
Notes Tables  
Schedule of restructuring charges The related restructuring charges for the year ended June 30, 2023 were recorded in the income statement as follows (in thousands):

Employee

Asset

    

severance

    

impairment and other

    

Total

Selling, general and administrative

$

1,328

$

842

$

2,170

Employee

Asset

    

severance

    

impairment and other

    

Total

Expense incurred in the first quarter of 2023

$

1,328

$

842

$

2,170

Cash payments

(1,233)

(772)

(2,005)

Adjustments

(95)

(70)

(165)

Accrued restructuring actions balances as of June 30, 2023

$

$

$

Protein Sciences | Employee severance  
Notes Tables  
Schedule of restructuring charges Restructuring actions, including cash and non-cash impacts, are as follows (in thousands):

Employee

severance

Expense incurred in fiscal year 2023

$

1,677

Fiscal year 2023 cash payments

(762)

Fiscal year 2023 adjustments

(18)

Accrued restructuring actions balances as of June 30, 2023

$

897

Fiscal year 2024 cash payments

(1,006)

Fiscal year 2024 adjustments(1)

221

Accrued restructuring actions balances as of March 31, 2024(2)

$

112

(1) Fiscal year 2024 adjustments relate to the refinement of the accrual recorded in fiscal year 2023.

(2) The remaining balance as of March 31, 2024 relates to employee severance that is paid out over a one-year period.